Analyst estimates USD 3.5bn peak sales for new Genmab drug
”Considering the data that has been presented, it comes as no surprise that the drug was approved,” says an analyst on Genmab’ and AbbVie’s recent approval.
by marketwire, translated by daniel pedersen
The approval of Genmab’s cancer drug, epcoritamab, from the US Food and Drug Administration (FDA) was far from a surprise – and is therefore already largely factored into the biotech company’s stock price.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA approves cancer drug Epkinly from Genmab and Abbvie
For subscribers
